Bibliografia UJ CM

1/5
G. Bianchi, E[dward] Czerwinski, A. Kenwright, A. Burdeska, R.R. Recker, D. Felsenberg.
Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis : 5-year data from the DIVA study long-term extension.
Osteoporosis International
2012 : Vol. 23, nr 6, s. 1769-1778, il., bibliogr. 40 poz., abstr.
p-ISSN: 0937-941X
AZ
ORG
AIF
IF: 4.039
2/5
D. Felsenberg, E[dward] Czerwinski, J. Stakkestad, C. Neate, D. Masanauskaite, J.Y. Reginster.
Efficacy of monthly oral ibandronate is maintained over 5 years : the Mobile LTE study.
Osteoporosis International
2009 : Vol. 20 suppl. 1, s. S 15, abstr. OC 32
Ninth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis ECCEO 9 - IOF, Athens, Greece, 18 - 21 March 2009
SZZ
SIF
3/5
R.R. Recker, L[ouis] G. Ste-Marie, E[dward] Czerwinski, L. Rowell, B. Bonvoisin, D. Masanauskaite, D. Felsenberg.
Intermittent intravenous ibandronate injections have a similar bone safety profile to daily oral dosing.
Calcif. Tissue Int.
2006 : Vol. 78 suppl. 1, s. S156, abstr. P455
33rd European Symposium on Calcified Tissues, Prague, Czech Republic, 10-14 May 2006.
SZZ
SIF
4/5
L.B. Tanko, D. Felsenberg, E[dward] Czerwiński, A. Burdeska, I. Jonkanski, C. Hughes, C. Christiansen, The Oral Ibandronate Group.
Oral weekly ibandronate prevents bone lossin postmenopausal women.
Journal of Internal Medicine
2003 : Vol. 254, nr 2, s. 159-167, il., bibliogr. 18 poz.
AZ
ORG
AIF
IF: 3.250
Streszczenie w PubMed:
DOI:
5/5
D. Felsenberg, C. Christiansen, E[dward] Cerwinski, A. Burdeska, I. Jonkanski, R. Meinert, The Oral Ibandronate Study Group.
Weekly dosing of oral ibandronate is effective in the prevention of postmenopausal osteoporosis.
Osteoporosis International
2002 : Vol. 13 suppl. 1, s. S16, poster P42SU.
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ